Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
I noticed that on Nov 9, a price of 0.76 US was applied to my Zenith shares. Previously it showed a price of 1.00 with no value attached.
TD told me that they had received the price information from an independent source but had no information.